Valuation: BriaCell Therapeutics Corp.

Market Cap 29.96M 27.15M 25.11M 22.66M 42.7M 2.83B 44.21M 302M 120M 1.51B 112M 110M 4.79B P/E 2025
-0.12x
P/E 2026 -0.49x
Enterprise Value 9.42M 8.54M 7.9M 7.13M 13.43M 888M 13.9M 94.86M 37.62M 475M 35.36M 34.61M 1.51B EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
99.86%
Yield 2025 *
-
Yield 2026 -
10-28 BriaCell Therapeutics Corp. Reports Earnings Results for the Full Year Ended July 31, 2026 CI
10-27 BriaCell Therapeutics Corp. Auditor Raises 'Going Concern' Doubt CI
10-23 Briacell Therapeutics Corp. Announces Clinical Biomarker Findings from Prospective Pooled Analysis of Patients with Metastatic Breast Cancer Treated with Immune Based Therapies Including the Briacell Regimen CI
09-14 BriaCell Therapeutics Corp Receives Seventh Consecutive Positive DSMB Recommendation For Pivotal Phase 3 Bria-ABC Study Of Bria-IMT Plus Immune Checkpoint Inhibitor CI
09-11 Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer CI
09-08 BriaCell Therapeutics Corp. Expands Pivotal Phase 3 Metastatic Breast Cancer Study To Memorial Sloan Kettering Cancer Center CI
09-01 Certain Common Shares of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-01 Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-01 Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-01 Certain Restricted Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-01 Certain Performance Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
08-24 BriaCell Therapeutics Corp. Advances Personalized Melanoma Immunotherapy Vaccine Candidate Bria-MEL+ CI
08-05 BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study MT
1 day-0.20%
1 week-12.21%
Current month+13.72%
1 month-8.77%
3 months+3.38%
6 months+18.40%
Current year-50.10%
1 week 4.76
Extreme 4.76
5.32
1 month 4.15
Extreme 4.15
5.79
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
18
3 years 3.68
Extreme 3.68
1,200
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 2016-10-31
Director of Finance/CFO 54 2016-01-31
Chief Tech/Sci/R&D Officer 65 2022-02-15
Director TitleAgeSince
Director/Board Member 70 2016-10-31
Chairman 41 2019-04-23
Director/Board Member 74 2019-03-06
Date Insider Type Main position Quantity % Market Cap. Importance
7/7/26 Tax

Director

45,000 0.5173%
7/7/26 Tax

Director

15,000 0.1724%
7/7/26 Option

Chief Financial Officer

28,257 0.3248%
Change 5-day change 1-year change 3-year change Capi.($)
-0.20%-12.21%-62.18%-99.44% 29.96M
-2.69%-0.48%+53.97%+66.82% 66.33B
+0.23%+3.12%+11.11%+95.64% 60.62B
+1.26%+2.24%+24.99%+90.83% 55.5B
+0.14%+2.35%+13.86%+111.94% 47.58B
-2.21%-2.47%+20.18%+28.81% 43.69B
-2.30%-10.40%+154.30%+707.36% 37.27B
+2.15%+1.42%+14.58%+48.71% 36.57B
+3.26%-2.84%+80.06%+61.98% 32.22B
+2.62%+5.90%-37.29%+386.59% 26.58B
Average +0.22%-1.18%+27.36%+149.92% 41B
Weighted average by Cap. -0.05%+0.20%+37.04%+153.22%

Financials

2025 2026
Net sales - -
Net income -26.31M -23.84M -22.05M -19.9M -37.5M -2.48B -38.82M -265M -105M -1.33B -98.74M -96.65M -4.21B -34.9M -31.63M -29.26M -26.4M -49.74M -3.29B -51.5M -351M -139M -1.76B -131M -128M -5.58B
Net Debt -17.87M -16.19M -14.98M -13.51M -25.46M -1.68B -26.36M -180M -71.33M -900M -67.05M -65.62M -2.86B -20.54M -18.61M -17.22M -15.53M -29.27M -1.94B -30.31M -207M -82.01M -1.03B -77.08M -75.45M -3.28B
Projected Income Statement - Annual - BriaCell Therapeutics Corp.
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
31
Date Price Change Volume
26-11-13 $4.890 -0.20% 1,848
26-11-12 $4.900 -3.54% 1,120
26-11-11 $5.080 -2.31% 201
26-11-10 $5.200 0.00% 1,223
26-11-09 $5.200 -6.64% 5,132